Cholangitis and Interruptions of Neoadjuvant Chemotherapy Associate with Reduced Overall and Progression-Free Survival in Pancreatic Cancer.
Biliary decompression
Cholangitis
Neoadjuvant treatment
Pancreatic cancer
Survival
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
28 Dec 2023
28 Dec 2023
Historique:
received:
05
04
2023
accepted:
06
12
2023
medline:
28
12
2023
pubmed:
28
12
2023
entrez:
28
12
2023
Statut:
aheadofprint
Résumé
Interrupting chemotherapy may explain the reduced overall survival (OS) in patients with pancreatic cancer (PC) with cholangitis. Endoscopic biliary decompression (BD) with metallic stents results in fewer chemotherapy interruptions and a lower cholangitis rate compared with plastic stents. We aimed to determine the impact of cholangitis, neoadjuvant treatment (NAT) interruptions and biliary stent choice on PC patients' survival. We conducted a retrospective analysis of 162 patients with cancer of the head of the pancreas undergoing pancreatoduodenectomy after NAT and BD documenting progression-free survival (PFS) and OS. Data on BD, cholangitis, stent type, surgical radicality, and chemotherapy were collected. Survival was estimated based on the Kaplan-Meier method by using the log-rank test and multivariate Cox regression analysis. Median OS and PFS for patients with cholangitis (n = 33, 20%) were 26 and 8 months (95% confidence interval [CI] 20-32 and 5-10 months), respectively, compared with 36 and 17 months (95% CI 31-41 and 12-21 months; p < 0.001 for OS; p = 0.002 for PFS) for patients without cholangitis. Among patients without NAT interruptions median OS and PFS were 35 and 17 months (95% CI 31-40 and 12-21 months), falling to 26 and 7 months (95% CI 18-30 and 5-10 months) among those who experienced an NAT interruption caused by biliary stent failure (n = 26, 16%) (p = 0.039 for OS; p < 0.001 for PFS). We found no difference in OS or PFS between stent types. Cholangitis and NAT interruptions reduce OS and PFS among PC patients.
Sections du résumé
BACKGROUND
BACKGROUND
Interrupting chemotherapy may explain the reduced overall survival (OS) in patients with pancreatic cancer (PC) with cholangitis. Endoscopic biliary decompression (BD) with metallic stents results in fewer chemotherapy interruptions and a lower cholangitis rate compared with plastic stents. We aimed to determine the impact of cholangitis, neoadjuvant treatment (NAT) interruptions and biliary stent choice on PC patients' survival.
METHODS
METHODS
We conducted a retrospective analysis of 162 patients with cancer of the head of the pancreas undergoing pancreatoduodenectomy after NAT and BD documenting progression-free survival (PFS) and OS. Data on BD, cholangitis, stent type, surgical radicality, and chemotherapy were collected. Survival was estimated based on the Kaplan-Meier method by using the log-rank test and multivariate Cox regression analysis.
RESULTS
RESULTS
Median OS and PFS for patients with cholangitis (n = 33, 20%) were 26 and 8 months (95% confidence interval [CI] 20-32 and 5-10 months), respectively, compared with 36 and 17 months (95% CI 31-41 and 12-21 months; p < 0.001 for OS; p = 0.002 for PFS) for patients without cholangitis. Among patients without NAT interruptions median OS and PFS were 35 and 17 months (95% CI 31-40 and 12-21 months), falling to 26 and 7 months (95% CI 18-30 and 5-10 months) among those who experienced an NAT interruption caused by biliary stent failure (n = 26, 16%) (p = 0.039 for OS; p < 0.001 for PFS). We found no difference in OS or PFS between stent types.
CONCLUSIONS
CONCLUSIONS
Cholangitis and NAT interruptions reduce OS and PFS among PC patients.
Identifiants
pubmed: 38153645
doi: 10.1245/s10434-023-14793-6
pii: 10.1245/s10434-023-14793-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24(43):4846–61.
doi: 10.3748/wjg.v24.i43.4846
pubmed: 30487695
pmcid: 6250924
Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694–705.
doi: 10.3748/wjg.v22.i44.9694
pubmed: 27956793
pmcid: 5124974
Luo J, Xiao L, Wu C, Zheng Y, Zhao N. The incidence and survival rate of population-based pancreatic cancer patients: Shanghai Cancer Registry 2004–2009. PloS One. 2013;8(10):e76052.
doi: 10.1371/journal.pone.0076052
pubmed: 24130758
pmcid: 3794034
Aaltonen P, Carpén O, Mustonen H, et al. Long-term nationwide trends in the treatment of and outcomes among pancreatic cancer patients. Eur J Surg Oncol. 2022;48(5):1087–92.
doi: 10.1016/j.ejso.2021.11.116
pubmed: 34844817
Nikšić M, Minicozzi P, Weir HK, et al. Pancreatic cancer survival trends in the US from 2001 to 2014: a CONCORD‐3 study. Cancer Communications. 2022 Nov 9.
Seppänen H, Juuti A, Mustonen H, et al. The results of pancreatic resections and long-term survival for pancreatic ductal adenocarcinoma: a single-institution experience. Scand J Surg. 2017;106(1):54–61.
doi: 10.1177/1457496916645963
pubmed: 27130378
Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2020;70:7–30.
doi: 10.3322/caac.21590
pubmed: 31912902
Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242):2008–20.
doi: 10.1016/S0140-6736(20)30974-0
pubmed: 32593337
Strobel O, Neoptolemos J, Jäger D, Büchler MW. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol. 2019;16:11–26.
doi: 10.1038/s41571-018-0112-1
pubmed: 30341417
Bockhorn M, Uzunoglu FG, Adham M, et al. Borderline resectable pancreatic cancer: a consensus statement by the international study group of pancreatic surgery (ISGPS). Surgery. 2014;155(6):977–88.
doi: 10.1016/j.surg.2014.02.001
pubmed: 24856119
Abrams RA, Lowy AM, O’Reilly EM, et al. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009;16:1751–6.
doi: 10.1245/s10434-009-0413-9
pubmed: 19390900
Evans DB, Erickson BA, Ritch P. Borderline resectable pancreatic cancer: definitions and the importance of multimodality therapy. Ann Surg Oncol. 2010;17:2803–5.
doi: 10.1245/s10434-010-1285-8
pubmed: 20737218
Lopez NE, Prendergast C, Lowy AM. Borderline resectable pancreatic cancer: definitions and management. World J Gastroenterol. 2014;20(31):10740–51.
doi: 10.3748/wjg.v20.i31.10740
pubmed: 25152577
pmcid: 4138454
Brown Z, Heh V, Labiner H, et al. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis. BJS. 2023;110(1):34–42.
doi: 10.1093/bjs/znac354
Birrer DL, Golcher H, Casadei R, et al. Neoadjuvant therapy for resectable pancreatic cancer: a new standard of care. Pooled data from 3 randomized controlled trials. Ann Surg. 2021;274(5):713–20.
doi: 10.1097/SLA.0000000000005126
pubmed: 34334656
Unno M, Motoi F, Matsuyama Y, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05). Jpn J Clin Oncol. 2019;49(2):190–4.
doi: 10.1093/jjco/hyy190
pubmed: 30608598
Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022;40(11):1220–30.
doi: 10.1200/JCO.21.02233
pubmed: 35084987
Seufferlein T, Ettrich TJ. Treatment of pancreatic cancer-neoadjuvant treatment in resectable pancreatic cancer (PDAC). Transl Gastroenterol Hepatol. 2019;4:21.
doi: 10.21037/tgh.2019.03.05
pubmed: 30976724
pmcid: 6458347
Hackert T. Surgery for pancreatic cancer after neoadjuvant treatment. Ann Gastroenterol Surg. 2018;2:413–8.
doi: 10.1002/ags3.12203
pubmed: 30460344
pmcid: 6236102
Hackert T, Sachsenmaier M, Hinz U, et al. Locally advanced pancreatic cancer: neoadjuvant therapy with Folfirinox results in resectability in 60% of the patients. Ann Surg. 2016;264(3):457–63.
doi: 10.1097/SLA.0000000000001850
pubmed: 27355262
Conroy T, Hammel P, Hebbar M, et al. for the Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–406.
doi: 10.1056/NEJMoa1809775
pubmed: 30575490
Darnell EP, Wang TJ, Lumish MA, et al. Preoperative cholangitis is an independent risk factor for mortality in patients after pancreatoduodenectomy for pancreatic cancer. Am J Surg. 2021;221(1):134–40.
doi: 10.1016/j.amjsurg.2020.07.025
pubmed: 32847686
Sokal A, Chawki S, Nguyen Y, et al. Specificities of acute cholangitis in patients with cancer: a retrospective comparative study of 130 episodes. Eur J Clin Microbiol Infect Dis. 2022;41(1):143–6.
doi: 10.1007/s10096-021-04289-0
pubmed: 34415466
Nehme F, Lee JH. Preoperative biliary drainage for pancreatic cancer. Dig Endosc. 2021;34:428–38.
doi: 10.1111/den.14081
pubmed: 34275165
Vehviläinen S, Seppänen H, Nurmi A, et al. Use of self-expandable metallic stents for endoscopic biliary decompression decreases stent complications in pancreatic cancer patients receiving chemotherapy. Surg Endosc. 2022;36(1):614–20.
doi: 10.1007/s00464-021-08327-y
pubmed: 33534073
Decker C, Christein JD, Phadnis MA, Wilcox MC, Varadarajulu S. Biliary metal stents are superior to plastic stents for preoperative biliary decompression in pancreatic cancer. Surg Endosc. 2011;25(7):2364–7.
doi: 10.1007/s00464-010-1552-6
pubmed: 21373939
pmcid: 3116134
Tol JA, van Hooft JE, Timmer R, et al. Metal or plastic stents for preoperative biliary drainage in resectable pancreatic cancer. Gut. 2016;65:1981–7.
doi: 10.1136/gutjnl-2014-308762
pubmed: 26306760
Ballard DD, Rahman S, Ginnebaugh B, Khan A, Dua KS. Safety and efficacy of self-expanding metal stents for biliary drainage in patients receiving neoadjuvant therapy for pancreatic cancer. Endosc Int Open. 2018;06(06):714–21.
doi: 10.1055/a-0599-6190
Dumonceau J, Tringali A, Papanikolaou IS, et al. Endoscopic biliary stenting: indications, choice of stents and results: European society of gastrointestinal endoscopy (ESGE) clinical guideline–updated October 2017. Endoscopy. 2018;50:910–30.
doi: 10.1055/a-0659-9864
pubmed: 30086596
Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. Hoboken: Wiley; 2011.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.
doi: 10.1097/01.sla.0000133083.54934.ae
pubmed: 15273542
pmcid: 1360123
Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc. 1991;37(3):383–93.
doi: 10.1016/S0016-5107(91)70740-2
pubmed: 2070995
Niesen W, Hank T, Büchler M, Strobel O. Local radicality and survival outcome of pancreatic cancer surgery. Ann Gastroenterol Surg. 2019;3:464–75.
doi: 10.1002/ags3.12273
pubmed: 31549006
pmcid: 6749949
Kim BJ, Prakash L, Narula N, et al. Contemporary analysis of complications associated with biliary stents during neoadjuvant therapy for pancreatic adenocarcinoma. HPB. 2019;21(6):662–8.
doi: 10.1016/j.hpb.2018.10.009
pubmed: 30522947
van der Gaag NA, Rauws EA, van Eijck CH, et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med. 2010;362:129–37.
doi: 10.1056/NEJMoa0903230
pubmed: 20071702
Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol. 2020;38(16):1763–73.
doi: 10.1200/JCO.19.02274
pubmed: 32105518
pmcid: 8265386
Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomized, phase 3 trial. Lancet. 2017;389(10073):1011–24.
doi: 10.1016/S0140-6736(16)32409-6
pubmed: 28129987
Mas L, Schwarz L, Bachet J. Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives. Curr Opinion Oncol. 2020;32(4):356–63.
doi: 10.1097/CCO.0000000000000639
Demir IE, Jäger C, Schlitter AM, et al. R0 versus R1 resection matters after pancreaticoduodenectomy, and less after distal or total pancreatectomy for pancreatic cancer. Ann Surg. 2018;268(6):1058–68.
doi: 10.1097/SLA.0000000000002345
pubmed: 28692477
Gemenetzis G, Groot VP, Blair AB, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg. 2019;270(2):340–7.
doi: 10.1097/SLA.0000000000002753
pubmed: 29596120
Song W, Miao D-L, Chen L. Nomogram for predicting survival in patients with pancreatic cancer. OncoTargets Ther. 2018;11:539–45.
doi: 10.2147/OTT.S154599